The FDA faces significant challenges due to politicization, which may impact its long-term effectiveness and decision-making processes. An economist highlights that recent staffing and review changes reflect a strong influence from the Trump administration's political agenda.
A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration’s political agenda, according to an economist and public policy expert.
Original title: “Politicization runs deeper than ever at FDA, risking long-term impacts”